PSMD12 Inhibitors

Chemical inhibitors of PSMD12 can be characterized by their interaction with the proteasome, a complex protein assembly responsible for degrading unwanted or misfolded proteins tagged with ubiquitin. These inhibitors exert their effects by binding to the active sites within the proteasome, where PSMD12 is a significant component, leading to a halt in the protein's function. Bortezomib, Carfilzomib, MG-132, Oprozomib, Marizomib, Ixazomib, Delanzomib, Lactacystin, Epoxomicin, Salinosporamide A, MLN9708, and CEP-18770 are all compounds that target the proteolytic activity of the 26S proteasome, thus directly inhibiting the functional contribution of PSMD12.

Bortezomib and Carfilzomib are known to inhibit the 26S proteasome by binding to its catalytic core, which includes the subunits associated with PSMD12, thereby blocking the degradation of ubiquitinated proteins. MG-132 further inhibits the protease activities of the proteasome where PSMD12 is active, through reversible binding to its active sites. Similarly, Oprozomib inactivates the proteasome complex by binding to these active sites, which directly impairs PSMD12's role within the complex. The action of Marizomib, which irreversibly binds to the 20S core particle, affects the activity of PSMD12 by preventing the overall function of the proteasome. Ixazomib, through its selective and reversible inhibition of the 20S proteasome, impairs the activity of PSMD12 within this complex. Delanzomib specifically inhibits the chymotrypsin-like activity of the proteasome, which is essential to PSMD12's function in protein degradation. Lactacystin's irreversible binding to the active site of the proteasome specifically inhibits the proteolytic functions facilitated by PSMD12. Epoxomicin is a covalent binder to the active sites of the proteasome, thereby directly inhibiting the role of PSMD12 in proteolytic activity. Lastly, MLN9708, once activated, binds to the proteasome, inhibiting its enzymatic activity which includes the function of PSMD12 within the complex, effectively halting the protein degradation machinery in which PSMD12 plays an integral role.